New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Novavax, Inc.

NVAX

Healthcare Biotechnology

Novavax, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 64.7% from fiscal 2024.

Revenue
−3.05%
EPS
n/m
Free cash flow
n/m
Total debt
+19.3%

Quarter to September 2026, against a year earlier

7.78 0.05 +0.65%
Market cap
$1.3B
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
5/9
ROIC
0.00%
Net debt / EBITDA
−1.0×
Payout ratio
—

Revenue to profit Q3 FY2026, quarter to Sep 30, 2026

It lost $31.4M on $68.3M of revenue: $45.94 for every $100. Gross margin has fallen three quarters running, from 85.0% to 65.6%. What is an income statement?

Revenue to profit, in millions of dollars and as a share of revenue
Revenue68.3100.0%
Cost of revenue−23.5−34.4%
Gross profit44.865.6%
Research & development−52.4−76.8%
Selling, general & admin−23.6−34.6%
Operating income−31.3−45.8%
Other income, net+1.62.4%
Income tax−1.7−2.5%
Net income−31.4−45.9%
RevenueOperating incomeNet incomeNet margin (right axis)
Revenue, operating income and net income, four quarters
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue$147M$140M$57M$68M
Operating income$14M−$15M−$55M−$31M
Net income$18M−$9.5M−$53M−$31M
Net margin (right axis)11.9%−6.8%−94.2%−45.9%
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Revenue
68.30 56.70 139.51 147.14

+8 more quarters

Revenue Growth
(3.05%) (76.30%) (79.07%) 66.61%
Gross Profit
44.81 42.45 108.82 125.04
Operating Income
(31.28) (54.91) (15.43) 14.23
EBT
(29.65) (51.68) (8.51) 17.90
Income after Tax
(31.38) (53.39) (9.49) 17.53
Net Income Common
(31.38) (53.39) (9.49) 17.53
EPS (Diluted)
(0.19) (0.32) (0.06) 0.11
Shares (Diluted, Weighted)
164.92 164.57 163.28 173.10
Gross Margin
65.61% 74.87% 78.00% 84.98%
EBIT Margin
(45.80%) (96.84%) (11.06%) 9.67%
Net Profit Margin
(45.94%) (94.16%) (6.80%) 11.91%
EBITDA
(28.23) (51.85) (12.37) 19.36
EBIT
(31.28) (54.91) (15.43) 14.23

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026